

MagicTouch **PTA**

SIROLIMUS COATED PTA BALLOON CATHETER



EFFICACY
YOU EXPECT
SAFETY
YOU TRUST

MagicTouch PTA

SIROLIMUS COATED PTA BALLOON CATHETER

MagicTouch PTA is **World's First Polymer Free** Sirolimus Drug Coated Balloon catheter for the treatment of the Peripheral arteries; intended for treating De-Novo, Stenotic & In-Stent Restenotic lesions, Superficial femoral (SFA), Popliteal, Below The Knee (BTK) & Iliac arteries.

CIRCUMFERNATIAL COATING

- ✓ Sirolimus Coating done under low pressure inflation for uniform coating and distribution of drug.

NANOLUTE TECHNOLOGY

- ✓ Encapsulation of sub micron sized Sirolimus particles in phospholipid carriers for effective transfer to deepest layer of vessel.

MOST STUDIED SCB WITH IDE CLEARANCE

- ✓ Backed by 12 global clinical studies, studying over 4,000 patients worldwide, **MagicTouch PTA** stands as one of the most extensively evaluated therapies for addressing the complexities of peripheral artery disease.
- ✓ Minimal in-transit drug loss due to better re-wrap of balloon.
- ✓ Programmed drug release ensures that Sirolimus addresses therapeutic window.
- ✓ Presence of In-tissue Drug for treatment upto 120 days.
- ✓ Low tip entry profile for better trackability & deliverability.
- ✓ Being polymer-free, **MagicTouch PTA** minimizes the risk of chronic inflammation, supporting faster healing and long-term vessel health.
- ✓ Available in the widest range of sizes to treat large to small peripheral arteries. Compatible with any guidewire of your choice for seamless flexibility.
- ✓ Designated as a USFDA Breakthrough Device, received IDE approval for both BTK and SFA indications.

Ordering Information
& Compliance Chart



CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings & instructions for use can be found in the product labelling supplied with each device. For restricted use only in countries where product registered with applicable health authorities. Approved by USFDA for use in clinical trials only in select indications.